Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma. Mitchell JS et al. Sci Rep. 2015 Jul 24;5:12473. doi: 10.1038/srep12473. MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis. Lazareth A et al. Haematologica. 2015 Jul 23. pii: haematol.2015.127001. [Epub ahead of print]. Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of…
Daily postdilutional hemodiafiltration with FX800 polysulfone dialyzers for removing kappa light chains inmultiple myeloma-induced kidney injury. Tillmann FP. Indian J Nephrol. 2015 Jul-Aug;25(4):237-41. doi: 10.4103/0971-4065.158176. Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients withMultiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation. Satlin MJ et al. Biol Blood Marrow Transplant. 2015 Jul 3. pii: S1083-8791(15)00441-3. doi:…
Time to redefine Myeloma. Pratt G et al. Br J Haematol. 2015 Jul 27. doi: 10.1111/bjh.13620. [Epub ahead of print]. Outcomes of primary refractory multiple myeloma and the impact of novel therapies. Majithia N et al. Am J Hematol. 2015 Jul 27. doi: 10.1002/ajh.24131. [Epub ahead of print]. Limiting early mortality: Do’s and don’ts in the management of patients with newly diagnosed multiple myeloma. Gonsalves…
Optimizing the management of patients with spinal myeloma disease. Molloy S et al. Br J Haematol. 2015 Jul 17. doi: 10.1111/bjh.13577. [Epub ahead of print]. Measuring therapy-induced peripheral neuropathy: preliminary development and validation of the Treatment-induced Neuropathy Assessment Scale (TNAS). Mendoza TR et al. J Pain. 2015 Jul 22. pii: S1526-5900(15)00763-4. doi: 10.1016/j.jpain.2015.07.002. [Epub ahead of print]. High-dose therapy improves the bone remodelling…
Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. Ludwig H et al. Br J Haematol. 2015 Jul 7. doi: 10.1111/bjh.13582. [Epub ahead of print]. Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Voorhees PM et al. Br…
This paper, produced by an expert panel of the International Myeloma Working Group (IMWG), provides consensus updates on the disease definition of myeloma which now include validated biomarkers in addition to the presence of the traditional ‘CRAB’ criteria.
Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma. Watanabe T et al. PLoS One. 2015 Jun 26;10(6):e0128662. doi: 10.1371/journal.pone.0128662. High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma. Chhabra S et al. J…
Vasotropic light-chain amyloidosis and ischaemic cholangiopathy. Johnston EL et al. BMJ Case Rep. 2015 Jun 25;2015. pii: bcr2015210883. doi: 10.1136/bcr-2015-210883. Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. Cao X et al. J Hematol Oncol. 2015 Jun 24;8(1):74. [Epub ahead of print]. Hepatocyte growth factor measurement in AL amyloidosis. Abraham J et al Amyloid. 2015 Jun 8:1-5. [Epub ahead of…
Safety of a second-generation tyrosine kinase inhibitor and novel targeted therapy for the treatment of a patient with chronic myeloid leukemia and multiple myeloma. Katzel JA et al. Anticancer Drugs. 2015 Jun 23. [Epub ahead of print]. Haematalogical cancer: Elotuzumab reduces risk of multiple myeloma progression. [No authors listed]. Nat Rev Clin Oncol. 2015 Jun 23. doi: 10.1038/nrclinonc.2015.115. [Epub ahead of print]. Lenalidomide…
Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma. Zang M et al. Cancer Lett. 2015 Jun 23. pii: S0304-3835(15)00403-6. doi: 10.1016/j.canlet.2015.06.011. [Epub ahead of print]. Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Kandela I et al. Elife. 2015 Jun 25;4. doi: 10.7554/eLife.07072. KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models. Riz I et…